Practice-Changing Data in NSCLC from ASCO 2021

Conference Correspondent  - AACR & ASCO 2021 - Midyear Review
Mark A. Socinski, MD
Medical Oncologist, Thoracic Cancer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Dr Mark Socinski provides his insights into important new data on EGFR inhibitors and immunotherapy in the first-line setting for NSCLC.
Related Items
Faculty Perspectives: Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine
Maria E. Arcila, MD, Mark A. Socinski, MD, Lauren Welch, MSN, NP-C, AOCNP
Faculty Perspectives: Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine published on June 27, 2022
Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma
Mark A. Socinski, MD
Conference Correspondent  published on December 14, 2021 in Dual IO 2021 Year in Review
Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC
Mark A. Socinski, MD
Conference Correspondent  published on December 14, 2021 in Dual IO 2021 Year in Review
2021 Midyear Review: Non–Small-Cell Lung Cancer
Conference Correspondent  published on June 20, 2021 in AACR & ASCO 2021 - Midyear Review
Phase 2 Study of DM-CHOC-PEN in Patients with NSCLC with Central Nervous System Involvement
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Clinical Outcomes for Plasma-Based Genomic Profiling versus Tissue Testing in Advanced NSCLC (NILE)
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Pooled Analyses of Immune-Related Adverse Events and Efficacy from IMpower130, IMpower132, and IMpower150
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Anti–PD-L1 Therapy in Combination with Chemotherapy versus Immunotherapy Alone in First-Line NSCLC with PD-L1 Score 1% to 49%
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
Comparison of Aumolertinib and Gefitinib in First-Line Treatment of EGFR-Mutated NSCLC
Conference Correspondent  published on June 19, 2021 in AACR & ASCO 2021 - Midyear Review
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: